Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells

Ko Jiunn Liu, Li Fan Lu, Hui Ting Cheng, Yi Mei Hung, Sheng Ru Shiou, Jacqueline Whang-Peng, Shin Hun Juang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

To improve the efficacy of tumor cell-based and dendritic cell (DC)-based cancer vaccines, this study explored the potential of a new cancer vaccine strategy, that is, the use of CD40 ligand-transfected tumor (CD40L-tumor) cells to simultaneously deliver both tumor-derived antigens (Ag) and maturation stimuli to DCs. Materials from frozen/thawed or irradiated human tumor cells, with or without surface CD40L, were internalized efficiently by immature DCs after coincubation. However, during the internalization process, only coculturing with irradiated CD40L-tumor cells resulted in concurrent, optimal DC maturation and production of proinflammatory chemokines and pro-Th1 cytokines, such as IL-6, IL-8, IL-12, IFN-γ, and TNF-α. These activated DCs were the most potent cells to support the growth of CD8 +, IFN-γ-producing T cells, and to process tumor Ag for the generation of specific cytotoxic T cells in vitro. Animals vaccinated with irradiated CD40L-tumor cell-pulsed DCs were better protected against subsequent challenge of a weakly immunogenic tumor cell line than animals vaccinated with irradiated CD40L-tumor cells alone. Thus, our results strongly support the future clinical application of using DCs pulsed with irradiated CD40L-tumor cells as a cancer vaccine.

Original languageEnglish
Pages (from-to)135-147
Number of pages13
JournalCancer Gene Therapy
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2004
Externally publishedYes

Fingerprint

CD40 Ligand
Neoplasm Antigens
Dendritic Cells
T-Lymphocytes
Cancer Vaccines
Neoplasms
Interleukin-12
Tumor Cell Line
Interleukin-8
Chemokines
Interleukin-6
Cytokines
Growth

Keywords

  • Antigen processing
  • CD40 ligand
  • Dendritic cells

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells. / Liu, Ko Jiunn; Lu, Li Fan; Cheng, Hui Ting; Hung, Yi Mei; Shiou, Sheng Ru; Whang-Peng, Jacqueline; Juang, Shin Hun.

In: Cancer Gene Therapy, Vol. 11, No. 2, 01.02.2004, p. 135-147.

Research output: Contribution to journalArticle

@article{0fa2b1693a034c688615dfc23400d877,
title = "Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells",
abstract = "To improve the efficacy of tumor cell-based and dendritic cell (DC)-based cancer vaccines, this study explored the potential of a new cancer vaccine strategy, that is, the use of CD40 ligand-transfected tumor (CD40L-tumor) cells to simultaneously deliver both tumor-derived antigens (Ag) and maturation stimuli to DCs. Materials from frozen/thawed or irradiated human tumor cells, with or without surface CD40L, were internalized efficiently by immature DCs after coincubation. However, during the internalization process, only coculturing with irradiated CD40L-tumor cells resulted in concurrent, optimal DC maturation and production of proinflammatory chemokines and pro-Th1 cytokines, such as IL-6, IL-8, IL-12, IFN-γ, and TNF-α. These activated DCs were the most potent cells to support the growth of CD8 +, IFN-γ-producing T cells, and to process tumor Ag for the generation of specific cytotoxic T cells in vitro. Animals vaccinated with irradiated CD40L-tumor cell-pulsed DCs were better protected against subsequent challenge of a weakly immunogenic tumor cell line than animals vaccinated with irradiated CD40L-tumor cells alone. Thus, our results strongly support the future clinical application of using DCs pulsed with irradiated CD40L-tumor cells as a cancer vaccine.",
keywords = "Antigen processing, CD40 ligand, Dendritic cells",
author = "Liu, {Ko Jiunn} and Lu, {Li Fan} and Cheng, {Hui Ting} and Hung, {Yi Mei} and Shiou, {Sheng Ru} and Jacqueline Whang-Peng and Juang, {Shin Hun}",
year = "2004",
month = "2",
day = "1",
doi = "10.1038/sj.cgt.7700663",
language = "English",
volume = "11",
pages = "135--147",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells

AU - Liu, Ko Jiunn

AU - Lu, Li Fan

AU - Cheng, Hui Ting

AU - Hung, Yi Mei

AU - Shiou, Sheng Ru

AU - Whang-Peng, Jacqueline

AU - Juang, Shin Hun

PY - 2004/2/1

Y1 - 2004/2/1

N2 - To improve the efficacy of tumor cell-based and dendritic cell (DC)-based cancer vaccines, this study explored the potential of a new cancer vaccine strategy, that is, the use of CD40 ligand-transfected tumor (CD40L-tumor) cells to simultaneously deliver both tumor-derived antigens (Ag) and maturation stimuli to DCs. Materials from frozen/thawed or irradiated human tumor cells, with or without surface CD40L, were internalized efficiently by immature DCs after coincubation. However, during the internalization process, only coculturing with irradiated CD40L-tumor cells resulted in concurrent, optimal DC maturation and production of proinflammatory chemokines and pro-Th1 cytokines, such as IL-6, IL-8, IL-12, IFN-γ, and TNF-α. These activated DCs were the most potent cells to support the growth of CD8 +, IFN-γ-producing T cells, and to process tumor Ag for the generation of specific cytotoxic T cells in vitro. Animals vaccinated with irradiated CD40L-tumor cell-pulsed DCs were better protected against subsequent challenge of a weakly immunogenic tumor cell line than animals vaccinated with irradiated CD40L-tumor cells alone. Thus, our results strongly support the future clinical application of using DCs pulsed with irradiated CD40L-tumor cells as a cancer vaccine.

AB - To improve the efficacy of tumor cell-based and dendritic cell (DC)-based cancer vaccines, this study explored the potential of a new cancer vaccine strategy, that is, the use of CD40 ligand-transfected tumor (CD40L-tumor) cells to simultaneously deliver both tumor-derived antigens (Ag) and maturation stimuli to DCs. Materials from frozen/thawed or irradiated human tumor cells, with or without surface CD40L, were internalized efficiently by immature DCs after coincubation. However, during the internalization process, only coculturing with irradiated CD40L-tumor cells resulted in concurrent, optimal DC maturation and production of proinflammatory chemokines and pro-Th1 cytokines, such as IL-6, IL-8, IL-12, IFN-γ, and TNF-α. These activated DCs were the most potent cells to support the growth of CD8 +, IFN-γ-producing T cells, and to process tumor Ag for the generation of specific cytotoxic T cells in vitro. Animals vaccinated with irradiated CD40L-tumor cell-pulsed DCs were better protected against subsequent challenge of a weakly immunogenic tumor cell line than animals vaccinated with irradiated CD40L-tumor cells alone. Thus, our results strongly support the future clinical application of using DCs pulsed with irradiated CD40L-tumor cells as a cancer vaccine.

KW - Antigen processing

KW - CD40 ligand

KW - Dendritic cells

UR - http://www.scopus.com/inward/record.url?scp=0942268831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942268831&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700663

DO - 10.1038/sj.cgt.7700663

M3 - Article

VL - 11

SP - 135

EP - 147

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 2

ER -